Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp
Citizens Jmp lifted their price target on shares of Prelude Therapeutics from $3.00 to $6.00 and gave the stock a "market outperform" rating in a report on Wednesday...
MarketBeat·11d ago
More News
Prelude Therapeutics Earnings Report: Q4 Overview
read more...
Benzinga·12d ago
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday
Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·20d ago
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·1mo ago
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9% - Should You Sell?
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Down 0.9% - What's Next...
MarketBeat·1mo ago
Why Did PRLD Stock Surge 13% Today?
Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396.
Stocktwits·2mo ago
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·2mo ago
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest...
MarketBeat·3mo ago
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1% - What's Next?
Prelude Therapeutics (NASDAQ:PRLD) Trading 2.1% Higher - Time to Buy...
MarketBeat·3mo ago
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.